Prostate Cancer Clinical Trials in Miami, FL

Prostate Cancer Clinical Trials in Miami, FL

View the best 10 prostate cancer medical studies in Miami, Florida. Access promising new therapies by applying to a Miami-based Prostate Cancer clinical trial.

Trials in Miami, Florida

Here are the top 10 medical studies for prostate cancer in Miami, Florida

Image of GU Research Network in Omaha, United States.

64Cu-SAR-BBN +1 More

Radiotherapeutic Agent

Recruiting1 awardPhase 1 & 2
This trial hopes to find out if a new treatment is safe and effective in treating prostate cancer that can't be treated with another method.
Image of Washington University School of Medicine in Saint Louis, United States.

Antiandrogen Therapy

Hormone Therapy

Recruiting1 awardPhase 2
This triallooks at taking breaks from antiandrogen therapy in metastatic prostate cancer patients responding well to treatment. Doctors may be able to use this data to safely allow testosterone recovery.
Image of Dana-Farber - Harvard Cancer Center LAO in Boston, United States.

M1774

Enzyme Inhibitor

Recruiting1 awardPhase 2
This trial tests M1774, a drug taken by mouth, in patients with hard-to-treat prostate cancer with a specific genetic mutation. The drug aims to stop cancer cells from growing by blocking enzymes they need. It could help shrink or stabilize these difficult-to-treat tumors.
Image of Nebraska Cancer Specialists in Grand Island, United States.

Lorigerlimab +2 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial is testing whether adding lorigerlimab to standard treatments (docetaxel and prednisone) can slow down prostate cancer that has spread and is not responding to hormone therapy. Lorigerlimab helps the immune system fight cancer, while docetaxel kills cancer cells, and prednisone manages side effects. About 150 patients will participate, with some receiving the new combination and others receiving just the standard treatment.
Image of Arizona Urology Specialists, PLLC in Tucson, United States.

Relugolix +1 More

Hormone Therapy

Recruiting2 awardsPhase 3
This trial compared the safety and heart-related risks of two hormone-lowering medications, relugolix and leuprolide acetate, in adults with prostate cancer. These drugs help manage cancer by reducing testosterone levels. The study was discontinued, but patients can continue their treatment for a certain period. Relugolix is the first oral medication of its kind and was approved by the FDA based on previous study results.
Image of Nebraska Cancer Specialists in Omaha, United States.

177Lu-PSMA-617 +2 More

Radioisotope Therapy

Recruiting2 awardsPhase 3
This trial tests if adding a radioactive drug to standard hormone treatments can better treat men with advanced prostate cancer. The drug targets and kills cancer cells with radiation, while standard treatments block hormones that help cancer grow.
Image of Houston Metro Urology in Houston, United States.

Radiotherapy +1 More

Radiation

Recruiting2 awardsPhase 3
This trial is testing if adding a new medication to standard prostate cancer treatments can better delay the spread of cancer or death. The combination works by blocking male hormones, killing cancer cells, and lowering hormone levels.
Image of USC Norris Comprehensive Cancer Center in Los Angeles, United States.

PC14586 +1 More

Small Molecule

Recruiting1 awardPhase 1 & 2
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Image of UC San Diego Moores Cancer Center in La Jolla, United States.

Apalutamide +1 More

Antiandrogen

Recruiting1 awardPhase 3
This trial is testing if using apalutamide and hormone therapy around the time of surgery can help men with high-risk prostate cancer by reducing the hormones that help the cancer grow.
Image of Miami Cancer Institute in Miami, United States.

177Lu-PSMA-617 +3 More

Radioisotope Therapy

Recruiting1 awardPhase 1 & 2
This trial aims to test the safety and potential side effects of a combination treatment involving Lutetium-177 (177Lu)-PSMA-617, niraparib, and abirater

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.